Editorial
|
|
|
|
|
France's regional pharmacovigilance centres can do much to protect patients' health
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Uncertain efficacy, high toxicity
|
|
|
|
|
|
|
|
|
|
Choose imatinib, a better-known drug
|
|
|
|
|
|
|
|
|
|
Still no tangible advantage of intranasal administration
|
|
|
|
|
|
|
|
|
|
Application rejected in France
|
|
|
|
|
|
|
|
|
|
Continue to use a better-known TNF-alpha antagonist
|
|
|
|
Adverse Effects
|
|
|
|
|
Mostly psychotropics and sex hormones
|
|
|
|
|
|
|
|
|
|
|
|
Hypokalaemia and bradycardia are risk factors
|
|
|
|
|
|
|
|
|
|
Confirmation of known adverse effects
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
When distress is unbearable despite treatment
|
|
|
|
|
|
|
|
|
|
Clinical advantage with chlorhexidine
|
|
|
|
Outlook
|
|
|
|
|
Analysis and proposals
|
|
|
|
|
|
|
|
|
|
Trial protocols and raw data
|
|
|
|
|
|
|
|
|
|